This trial will test whether reducing blood phosphate levels for people with end-stage kidney disease will improve health outcomes and be cost-effective.
1 Primary · 3 Secondary · Reporting Duration: 5 years
Active Control
Experimental Treatment
3600 Total Participants · 2 Treatment Groups
Primary Treatment: Intensive phosphate target · No Placebo Group · N/A
Age 18+ · All Participants · 4 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: